Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 56Lymphoma, Large B-Cell, Diffuse 55Lymphoma, Follicular 48Lymphoma 47Leukemia, Lymphocytic, Chronic, B-Cell 45Lymphoma, Mantle-Cell 41Lymphoma, B-Cell, Marginal Zone 24Lymphoma, B-Cell 22Waldenstrom Macroglobulinemia 17Hodgkin Disease 16Burkitt Lymphoma 16Leukemia 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Recurrence 10Lymphoma, Large-Cell, Immunoblastic 9Neoplasms 7Multiple Myeloma 6Myelodysplastic Syndromes 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Anaplastic 4Lymphoma, Extranodal NK-T-Cell 4Leukemia, Hairy Cell 4Intraocular Lymphoma 4Hematologic Neoplasms 4Sezary Syndrome 3Mycosis Fungoides 3Lymphoma, T-Cell 3Lymphoma, Primary Effusion 3Immunoblastic Lymphadenopathy 3

Interventions

Etoposide 2prednylidene 1emvododstat 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Vorinostat 1Vincristine 1Rituximab 1Raltegravir Potassium 1Prednisone 1Polymerase Chain Reaction 1Peripheral Blood Stem Cell Transplantation 1Melphalan 1Lenalidomide 1Immunohistochemistry 1Genes 1Gene Expression Profiling 1Doxorubicin 1Cytarabine 1Cyclophosphamide 1Carmustine 1CT-P10 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × HIV Infections × Rituximab × Clear all
NCT01193842 2023-11-21

Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1/2 Completed
107 enrolled 24 charts
Lymphoid

Plasmablastic Lymphoma, Lymphoma, Follicular, HIV Infections, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡